Authors:
Modesitt, SC
Ramirez, P
Zu, ZF
Bodurka-Bevers, D
Gershenson, D
Wolf, JK
Citation: Sc. Modesitt et al., In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer - See The Biology Behind: M. E. Murphy, the battle between tumor suppressors: Is gene therapy using p16(INK4a) more efficacious than p53 for treatment of ovarian carcinoma? Clin. Cancer Res., 7: 1487-1489, 2001., CLIN CANC R, 7(6), 2001, pp. 1765-1772
Authors:
Brewer, M
Utzinger, U
Satterfield, W
Hill, L
Gershenson, D
Bast, R
Wharton, JT
Richards-Kortum, R
Follen, M
Citation: M. Brewer et al., Biomarker modulation in a nonhuman rhesus primate model for ovarian cancerchemoprevention, CANC EPID B, 10(8), 2001, pp. 889-893
Authors:
Malpica, A
Deavers, MT
Gershenson, D
Tortolero-Luna, G
Silva, EG
Citation: A. Malpica et al., Serous tumors involving extra-abdominal/extra-pelvic sites after the diagnosis of an ovarian serous neoplasm of low malignant potential, AM J SURG P, 25(8), 2001, pp. 988-996
Authors:
Donato, ML
Champlin, RE
Wharton, JT
Bodurka-Bevers, D
Gershenson, D
Citation: Ml. Donato et al., Intensive-dose ifosfamide and etoposide with filgrastim for cytoreduction before peripheral blood stem cell collection in patients with advanced ovarian cancer, EUR J GYN O, 21(3), 2000, pp. 241-244
Authors:
Donato, ML
Gershenson, D
Ippoliti, C
Wharton, JT
Bast, RC
Aleman, A
Anderlini, P
Gajewski, JG
Giralt, S
Molldrem, J
Ueno, N
Lauppe, J
Korbling, M
Boyer, J
Bodurka-Bevers, D
Bevers, M
Burke, T
Freedman, R
Levenback, C
Wolf, J
Champlin, RE
Citation: Ml. Donato et al., High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer, BONE MAR TR, 25(11), 2000, pp. 1137-1140
Authors:
Vadhan-Raj, S
Verschraegen, CF
Bueso-Ramos, C
Broxmeyer, HE
Kudelka, AP
Freedman, RS
Edwards, CL
Gershenson, D
Jones, D
Ashby, M
Kavanagh, JJ
Citation: S. Vadhan-raj et al., Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer, ANN INT MED, 132(5), 2000, pp. 364-368
Authors:
Mills, GB
Schmandt, R
Gershenson, D
Bast, RC
Citation: Gb. Mills et al., Should therapy of ovarian cancer patients be individualized based on underlying genetic defects?, CLIN CANC R, 5(9), 1999, pp. 2286-2288
Authors:
Silva, EG
Tornos, C
Deavers, M
Kaisman, K
Gray, K
Gershenson, D
Citation: Eg. Silva et al., Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation, GYNECOL ONC, 71(2), 1998, pp. 240-246